PT  - JOURNAL ARTICLE
AU  - Eliza Thomas
AU  - Phil J Peacock
AU  - Sarah E Bates
TI  - Variation in the management of SSRI-exposed babies across England
AID  - 10.1136/bmjpo-2017-000060
DP  - 2017 Aug 01
TA  - BMJ Paediatrics Open
PG  - e000060
VI  - 1
IP  - 1
4099  - http://bmjpaedsopen.bmj.com/content/1/1/e000060.short
4100  - http://bmjpaedsopen.bmj.com/content/1/1/e000060.full
AB  - Background Depression in pregnancy is commonly treated using selective serotonin reuptake inhibitors (SSRIs). A possible withdrawal syndrome following in utero exposure has been reported, but there is currently no UK guidance on the management of these neonates.Methods All 160 neonatal units in England were asked for information regarding their management of SSRI-exposed babies.Results Responses were obtained from 112/160 (70%) units. Only four units had a specific protocol for managing SSRI-exposed neonates. Twenty-one units (19%) conduct routine observations on exposed neonates, while 37 units (33%) would consider treating babies with signs of withdrawal or toxicity.Conclusions Very few neonatal units in England have specific guidelines for the management of babies exposed to SSRIs in utero, with practice varying greatly between units. Further research is needed on the outcomes of SSRI-exposed babies to support development of standardised evidence-based guidelines to ensure all mothers and babies receive similar high-quality care.